Dr. John Greden to discuss GeneSight study results at upcoming APA annual meeting in May 2018
Nov. 02, 2017 — Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
“From a clinician’s perspective, better but not well is not good enough and significant improvements in response and remission are always the most-desired endpoints,” said John Greden, M.D., Founding Chair of the National Network of Depression Centers (NNDC). “We are eager to discuss complete results from this study as well as potential future applications of pharmacogenomics at the upcoming APA annual meeting in May 2018.”
